A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients
An Open, Non-randomised, Multi-centre Phase I Study to Assess the Safety and Efficacy of Fluzoparib Given in Combination With Apatinib and Paclitaxel in the 2nd Line Treatment of Patients With Recurrent or Metastatic Gastric Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Jianming Xu, MD
- Email: jmxu2003@yahoo.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100039
- Recruiting
- The Affiliated Hospital of Military Medical Sciences
-
Contact:
- Jianming Xu, MD
- Email: jmxu2003@yahoo.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- ECOG performance status of 0 to 1.
- Life expectancy of more than 12 weeks.
- Histologically or cytologically confirmed gastric adenocarcinoma( adenocarcinoma of the gastroesophageal junction included).
- Recurrent or metastatic gastric cancer that has progressed following first line-therapy.
- At least one lesion (measurable and/or non-measurable) that can be accurately assessed by imaging (CT/MRI) at baseline
- Subjects who have overall good overall general condition.
- Signed informed consent.
Exclusion Criteria:
- Subjects who received any previous treatment with any PARP inhibitors.
- Subjects who received any previous treatment with any taxanes.
- More than one prior chemotherapy regimen for the treatment of gastric cancer in the metastatic or recurrent setting.
- Less than 4 weeks from the last clinical trial.
- Less than 2 weeks from the last radiotherapy, chemotherapy, surgery, hormone treatment and target therapy.
- Unstable hypertension.
- Subjects that are unable to swallow, or dysfunction of gastrointestinal absorption.
- Subjects with brain metastases.
- Subjects with uncontrolled hypokalemia and hypomagnesemia before study entry.
- Subjects with a known hypersensitivity to fluzoparib, apatinib, paclitaxel or any of the excipients of the product.
- Ongoing infection (determined by investigator).
- History of immunodeficiency, including HIV-positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation.
- Subjects who can not interrupt the using of the drugs that may cause QT prolongation during study.
- Pregnant or breast-feeding women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Fluzoparib + Apatinib + Paclitaxel
|
Intravenous injection
Oral
Fluzoparib either at 20,30,40mg twice daily,capsule oral.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
DLT and safety: Adverse Events (AEs), physical examination, vital signs including blood pressure (BP), pulse, electrocardiogram (ECG) and laboratory findings including clinical chemistry, hematology, urinalysis.
Time Frame: through study completion, an average of 6 months
|
DLT and safety defined by CTC version 4.0
|
through study completion, an average of 6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Best of ORR
Time Frame: through study completion, an average of 6 months
|
through study completion, an average of 6 months
|
|
Overall Response Rate (ORR)
Time Frame: through study completion, an average of 6 months
|
through study completion, an average of 6 months
|
|
Disease Control Rate (DOR)
Time Frame: through study completion, an average of 6 months
|
through study completion, an average of 6 months
|
|
Time to Progression (TTP)
Time Frame: From date of enrollment until the date of first objective progression, assessed up to 9 months
|
From date of enrollment until the date of first objective progression, assessed up to 9 months
|
|
Progression Free Survival (PFS)
Time Frame: From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, an average of 6 months
|
From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, an average of 6 months
|
|
Maximum plasma concentration (Cmax)
Time Frame: Up to 33 days
|
Up to 33 days
|
|
Terminal half life (t1/2)
Time Frame: Up to 33 days
|
Up to 33 days
|
|
Area under the plasma concentration-time curve (AUC)
Time Frame: Up to 33 days
|
Up to 33 days
|
|
Volume of distribution (V/F)
Time Frame: Up to 33 days
|
Up to 33 days
|
|
Plasma Clearance (CL/F)
Time Frame: Up to 33 days
|
Up to 33 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Stomach Diseases
- Stomach Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Protein Kinase Inhibitors
- Paclitaxel
- Apatinib
Other Study ID Numbers
Other Study ID Numbers
- FZPL-I-103-GC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.